Drugs / Lactobacillus acidophilus L92
Lactobacillus acidophilus L92
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04517045 | Oct 2020 → Jul 2022 | — | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00554736 | May 2006 → Dec 2007 | allergic rhinitis | University of California, Davis | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus acidophilus L92 | “Lactobacillus acidophilus L92” NCT04517045 ↗ |
| Known as | L-92 | “The active product to be used is a tablet made from desiccated Lactobacillus acidophilus strain L-92 and fillers.” NCT00554736 ↗ |
| Known as | L. acidophilus (L92) | “CALPIS has selected a strain of lactobacilli, L. acidophilus (L92), on the basis of an IgE- lowering effect in experimental studies with mice.” NCT00554736 ↗ |
| Known as | Lactobacillus acidophilus strain L-92 | “The active product to be used is a tablet made from desiccated Lactobacillus acidophilus strain L-92 and fillers.” NCT00554736 ↗ |
| Modality | Other / unclassified | “The overall objective of this study is to establish the benefit of a bacterial product, Lactobacillus acidophilus strain L-92” NCT00554736 ↗ |
| Route | Oral | “L92 2 tablets/time, tid, oral or nasal feeding” NCT04517045 ↗ |
| Route | Other | “L92 2 tablets/time, tid, oral or nasal feeding” NCT04517045 ↗ |